AR026255A1 - Combinaciones antivirales. - Google Patents
Combinaciones antivirales.Info
- Publication number
- AR026255A1 AR026255A1 ARP000105645A ARP000105645A AR026255A1 AR 026255 A1 AR026255 A1 AR 026255A1 AR P000105645 A ARP000105645 A AR P000105645A AR P000105645 A ARP000105645 A AR P000105645A AR 026255 A1 AR026255 A1 AR 026255A1
- Authority
- AR
- Argentina
- Prior art keywords
- hbv
- combinations
- refers
- nucleoside
- antiviral combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a combinaciones terapéuticas que comprenden (2R,cis)-4-amino-1-(2-hidroximetil)-1,3-oxatiolán-5-il)-pirimidín-2-ona (lamivudine), y BMS.200475,que tienen una actividad anti-HBV (contra el virus de la Hepatitis B). Se refiere también a comp osiciones faramcéuticas que contienen dichas combinaciones y asu utilizacion en el tratamiento de las infecciones por HBV que incluyen las infeciones causadas por los mutantes del HBV que llevan una resistencia contra losinhibidores nucleosidos y no nucleosidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/429,863 US6432966B2 (en) | 1999-10-29 | 1999-10-29 | Antiviral combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
AR026255A1 true AR026255A1 (es) | 2003-02-05 |
Family
ID=23705033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105645A AR026255A1 (es) | 1999-10-29 | 2000-10-26 | Combinaciones antivirales. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6432966B2 (es) |
EP (1) | EP1225904B1 (es) |
JP (1) | JP2003512421A (es) |
AR (1) | AR026255A1 (es) |
AT (1) | ATE273012T1 (es) |
AU (1) | AU1042701A (es) |
DE (1) | DE60012961T2 (es) |
ES (1) | ES2225245T3 (es) |
TW (1) | TWI282735B (es) |
WO (1) | WO2001030329A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064221A1 (en) † | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Co. | Low dose entecavir formulation and use |
US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
US8168568B1 (en) * | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Cdca1抗原決定位胜肽及含此胜肽的疫苗 |
CN102552210B (zh) * | 2012-01-10 | 2013-12-11 | 四川海思科制药有限公司 | 一种恩替卡韦胶囊组合物及其制备方法 |
CA2982125A1 (en) * | 2015-04-07 | 2016-10-13 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hbv infection |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9800452D0 (sv) * | 1998-02-13 | 1998-02-13 | Medivir Ab | Antivirals |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
US5206244A (en) | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
EP0513917B2 (en) * | 1991-05-16 | 2001-03-07 | Glaxo Group Limited | Antiviral combinations containing nucleoside analogs |
IL113432A (en) | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
AU748594B2 (en) * | 1997-04-15 | 2002-06-06 | Ohr Pharmaceutical, Inc. | A combination therapy for HIV infections |
CN1279610A (zh) * | 1997-09-25 | 2001-01-10 | 康奈尔研究基金会股份有限公司 | 抑制肝癌发展和提高慢性肝dna病毒感染者存活率的方法 |
-
1999
- 1999-10-29 US US09/429,863 patent/US6432966B2/en not_active Expired - Lifetime
-
2000
- 2000-10-26 AR ARP000105645A patent/AR026255A1/es not_active Application Discontinuation
- 2000-10-27 ES ES00971593T patent/ES2225245T3/es not_active Expired - Lifetime
- 2000-10-27 JP JP2001532749A patent/JP2003512421A/ja active Pending
- 2000-10-27 AT AT00971593T patent/ATE273012T1/de not_active IP Right Cessation
- 2000-10-27 EP EP00971593A patent/EP1225904B1/en not_active Expired - Lifetime
- 2000-10-27 TW TW089122670A patent/TWI282735B/zh not_active IP Right Cessation
- 2000-10-27 WO PCT/GB2000/004137 patent/WO2001030329A2/en active IP Right Grant
- 2000-10-27 AU AU10427/01A patent/AU1042701A/en not_active Abandoned
- 2000-10-27 DE DE60012961T patent/DE60012961T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US6432966B2 (en) | 2002-08-13 |
US20020002180A1 (en) | 2002-01-03 |
TWI282735B (en) | 2007-06-21 |
WO2001030329A2 (en) | 2001-05-03 |
ES2225245T3 (es) | 2005-03-16 |
AU1042701A (en) | 2001-05-08 |
DE60012961T2 (de) | 2005-08-18 |
JP2003512421A (ja) | 2003-04-02 |
ATE273012T1 (de) | 2004-08-15 |
WO2001030329A3 (en) | 2001-11-01 |
DE60012961D1 (de) | 2004-09-16 |
EP1225904A2 (en) | 2002-07-31 |
EP1225904B1 (en) | 2004-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW366347B (en) | Antiviral pharmaceutical compositions comprising 1,3-oxathiolane nucleoside analogues | |
RU94013464A (ru) | Нуклеозидные аналоги 1,3-оксатиолана, способ получения, фармацевтическая композиция, способ лечения вирусной инфекции | |
MY109796A (en) | 1,3-oxathiolane nucleoside analogues. | |
RS20120201A3 (en) | METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C | |
DK1658302T3 (da) | Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C | |
EA199700203A1 (ru) | Синергические комбинации зидовудина, 1592u89 и 3тс или ftc | |
PA8588501A1 (es) | Derivados antivirales de nucleósidos | |
UY29868A1 (es) | Nucleocidos 4 modificados como agentes antivirales | |
ES2138969T3 (es) | Combinacion de nucleosidos antivirales. | |
HK1068538A1 (en) | Antiviral compounds | |
AR026255A1 (es) | Combinaciones antivirales. | |
AR023661A1 (es) | Combinaciones antivirales | |
AR022250A1 (es) | Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b. | |
AR043332A1 (es) | Composiciones y metodos para terapia antiviral | |
RU2018147078A (ru) | Комбинация противовирусных средств, набор и способ лечения на ее основе | |
AR040805A1 (es) | Composiciones que contienen tenofovir y emtricitabina y metodos para terapia antiviral | |
RU2005138167A (ru) | Противовирусное средство (варианты) и способ лечения на его основе | |
WO2000018383A3 (en) | Antiviral combinations comprising (s)-2- ethyl-7- fluoro-3- oxo-3,4- dihydro-2h- quinoxaline-1- carboxylic acid isopropyl ester | |
WO2000016754A3 (en) | Antiviral combinations comprising lamivudine and lobucavir | |
DE602005006397D1 (de) | Nukleosidanaloga mit antiviraler wirkung | |
AR019532A1 (es) | COMPOSICIoN FARMACÉUTICA DEL COMPUESTO 1,5-DIDEOXI-1,5-IMIN-D-GLUCITOL N-SUSTITUIDO |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |